Publicaciones en colaboración con investigadores/as de Pontifícia Universidade Católica do Rio Grande do Sul (5)

2022

  1. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    Cancer, Vol. 128, Núm. 11, pp. 2085-2097

2020

  1. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588

  2. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

    European Journal of Cancer, Vol. 138, pp. 202-211

2018

  1. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma

    New England Journal of Medicine, Vol. 378, Núm. 14, pp. 1277-1290

  2. The clinical activity of PD-1/PD-L1 inhibitors in metastatic non–clear cell renal cell carcinoma

    Cancer Immunology Research, Vol. 6, Núm. 7, pp. 758-765